Accessibilité
Animation
Accessibilité

Molecular Tumor Board: 65-year-old male with recurrent hepatocellular carcinoma

In this molecular tumor board, our Medical Affairs Team presents a case of recurrent hepatocellular carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. We reviewed TIGIT as a promising target for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.